The role of proteomics in understanding biological mechanisms of sepsis

Proteomics - Clinical Applications

Volumn 8, Issue 1-2, 2014, Pages 35-52

  Cao, Zhiyun ^a   Robinson, Renã A S ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

MS; Sepsis; Septic shock; Severe sepsis; SIRS

Indexed keywords

BIOLOGICAL MARKER; CHAPERONE; PLASMA PROTEIN;

ACUTE PHASE RESPONSE; BLOOD CLOTTING; COMPLEMENT SYSTEM; ENERGY METABOLISM; HUMAN; INFLAMMATION; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; NEWBORN SEPSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; SEPSIS;

MS; SEPSIS; SEPTIC SHOCK; SEVERE SEPSIS; SIRS;

ANIMALS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; IMMUNITY, CELLULAR; MULTIPLE ORGAN FAILURE; PROTEOME; PROTEOMICS; SEPSIS; SHOCK, SEPTIC; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84893437825     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201300101     Document Type: Review

References (163)

1. Lever, A., Mackenzie, I., Sepsis: definition, epidemiology, and diagnosis. Br. Med. J. 2007, 335, 879-883.
2. Carrigan, S. D., Scott, G., Tabrizian, M., Toward resolving the challenges of sepsis diagnosis. Clin. Chem. 2004, 50, 1301-1314.
3. Nguyen, H. B., Rivers, E. P., Abrahamian, F. M., Moran, G. J. et al., Severe sepsis and septic shock: review of the literature and emergency department management guidelines. Ann. Emerg. Med. 2006, 48, 28-54.
4. Angus, D. C., van der Poll, T., Severe Sepsis and Septic Shock. N Engl. J. Med. 2013, 369, 840-851.
5. Cohen, J., The immunopathogenesis of sepsis. Nature 2002, 420, 885-891.
6. N, A. V., Urinary tract infection-a dangerous and unrecognised forerunner of systemic sepsis. J. Postgrad. Med. 1992, 38, 52-54.
7. Merrel, R. C., The abdomen as source of sepsis in critically ill patients. Crit. Care Clin. 1995, 11, 255-272.
8. Rangel-Frausto, M. S., Pittet, D., Costigan, M., Hwang, T. et al., The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. J. Am. Med. Assoc. 1995, 273, 117-123.
9. Kumar, G., Kumar, N., Taneja, A., Kaleekal, T. et al., Nationwide trends of severe sepsis in the 21st century (2000-2007). CHEST J. 2011, 140, 1223-1231.
10. Thomas, M., Peter, J. V., Williams, A., Job, V. et al., Systemic inflammatory response syndrome in diseases of the skin. Postgrad. Med. J. 2010, 86, 83-88.
11. Dremsizov, T., Clermont, G., Kellum, J. A., Kalassian, K. G. et al., Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course? Chest J. 2006, 129, 968-978.
12. Werdan, K., Pathophysiology of septic shock and multiple organ dysfunction syndrome and various therapeutic approaches with special emphasis on immunoglobulins. Ther. Apher. 2001, 5, 115-122.
13. Stevenson, E. K., Rubenstein, A. R., Radin, G. T., Wiener, R. S. et al., Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit. Care Med. 2013, doi:10.1097/CCM.0000000000000026.
14. Levinson, A. T., Casserly, B. P., Levy, M. M., Reducing mortality in severe sepsis and septic shock. Semin. Respir. Crit. Care Med. 2011, 32, 195-205.
15. Angus, D. C., Wax, R. S., Epidemiology of sepsis: an update. Crit. Care Med. 2001, 29, S109-S116.
16. Angus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont, G. et al., Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 2001, 29, 1303-1310.
17. Girard, T. D., Opal, S. M., Ely, E. W., Insights into severe sepsis in older patients: from epidemiology to evidence-based management. Clin. Inf. Dis. 2005, 40, 719-727.
18. Andrews, R., Elixhauser, A., The national hospital bill: growth trends and 2005 update on the most expensive conditions by payer. Healthcare Cost and Utilization Project. 2007, 1-13. Accessed May 2012 http://www.hcup-us.ahrq.gov/reports/statbriefs/sb42.pdf.
19. Carvalho, P. R. A., Trotta, E. d. A., Advances in sepsis diagnosis and treatment. J. Pediatr. 2003, 79, S195-S204.
20. Hotchkiss, R. S., Karl, I. E., The pathophysiology and treatment of sepsis. N. Engl. J. Med. 2003, 348, 138-150.
21. Rivers, E., Nguyen, B., Havstad, S., Ressler, J. et al., Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 2001, 345, 1368-1377.
22. Nguyen, H. B., Rivers, E. P., The clinical practice of early goal-directed therapy in severe sepsis and septic shock. Adv. Sepsis 2005, 4, 126-133.
23. Annane, D., Corticosteroids for severe sepsis: an evidence-based guide for physicians. Ann. Intensive Care 2011, 1, 7-7.
24. Keh, D., Sprung, C. L., Use of corticosteroid therapy in patients with sepsis and septic shock: an evidence-based review. Crit. Care Med. 2004, 32, S527-S523.
25. Casserly, B., Gerlach, H., Phillips, G. S., Marshall, J. C. et al., Evaluating the use of recombinant human activated protein C in adult severe sepsis: results of the surviving sepsis campaign. Crit. Care Med. 2012, 40, 1417-1426.
26. Fourrier, F., Recombinant human activated protein C in the treatment of severe sepsis: an evidence-based review. Crit. Care Med. 2004, 32, S534-S541.
27. Patel, G. P., Balk, R. A., Systemic steroids in severe Sepsis and septic shock. Am. J. Respir. Crit. Care Med. 2012, 185, 133-139.
28. Turgeon, A. F., Hutton, B., Fergusson, D. A., McIntyre, L. et al., Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann. Intern. Med. 2007, 146, 193-203.
29. Laupland, K. B., Kirkpatrick, A. W., Delaney, A., Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis*. Crit. Care Med. 2007, 35, 2686-2692.
30. Joannidis, M., The clinical application of CRRT current status: continuous renal replacement therapy in sepsis and multisystem organ failure. Semin. Dial. 2009, 22, 160-164.
31. Grootendorst, A. F., Bouman, C. S. C., Hoeben, K. H. N., van Saase, J. L. C. M. et al., The role of continuous renal replacement therapy in sepsis and multiorgan failure. Am. J. Kidney Dis. 1996, 28, S50-S57.
32. Albuszies, G., Brückner, U., Antioxidant therapy in sepsis. Intensive Care Med. 2003, 29, 1632-1636.
33. Berger, M. M., Chioléro, R. L., Antioxidant supplementation in sepsis and systemic inflammatory response syndrome. Crit. Care Med. 2007, 35, S584-S590.
34. Iba, T., Nagaoka, I., Boulat, M., The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation. Thromb. Res. 2013, 131, 383-389.
35. Ward, P. A., Guo, R., Riedemann, N. C., Manipulation of the complement system for benefit in sepsis. Crit. Care Res. Pract. 2012, 2012, 427607.
36. Freeman, B. D., Natanson, C., Anti-inflammatory therapies in sepsis and septic shock. Expert Opin. Investig. Drugs. 2000, 9, 1651-1663.
37. Wu, A., Hinds, C. J., Thiemermann, C., High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock 2004, 21, 210-221.
38. Hotchkiss, R. S., Monneret, G., Payen, D., Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect. Dis. 2013, 13, 260-268.
39. Venkataraman, R., Kellum, J. A., Sepsis: update in the management. Adv. Chronic Kidney Dis. 2013, 20, 6-13.
40. Ward, P. A., New approaches to the study of sepsis. EMBO Mol. Med. 2012, 4, 1234-1243.
41. An, G., Namas, R. A., Vodovotz, Y., Sepsis: from pattern to mechanism and back. Crit. Rev. Biomed. Eng. 2012, 40, 341-351.
42. Rivers, E. P., Jaehne, A. K., Nguyen, H. B., Papamatheakis, D. G. et al., Early biomarker activity in severe sepsis and septic shock and a contemporary review of immunotherapy trials: not a time to give up, but to give it earlier. Shock 2013, 39, 127-137.
43. Blanco, A., Solis, G., Arranz, E., Coto, G. D. et al., Serum levels of CD14 in neonatal sepsis by Gram-positive and Gram-negative bacteria. Acta Paediatr. 1996, 85, 728-732.
44. Blommendahl, J., Janas, M., Laine, S., Ari, M. et al., Comparison of procalcitonin with CRP and differential white blood cell count for diagnosis of culture-proven neonatal sepsis. Scand. J. Infect. Dis. 2002, 34, 620-622.
45. Kellum, J. A., Kong, L., Fink, M. P., Weissfeld, L. A. et al., Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the genetic and inflammatory markers of sepsis (GenIMS) study. Arch. Intern. Med. 2007, 167, 1655-1663.
46. Daniels, R., Surviving the first hours in sepsis: getting the basics right (an intensivist's perspective). J. Antimicrob. Chemother. 2011, 66, ii11-ii23.
47. Padkin, A., Goldfrad, C., Brady, A. R., Young, D. et al., Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit. Care Med. 2003, 31, 2332-2338.
48. Schouten, M., Wiersinga, W. J., Levi, M., van der Poll, T., Inflammation, endothelium, and coagulation in sepsis. J. Leukoc. Biol. 2008, 83, 536-545.
49. Esmon, C., Fukudome, K., Mather, T., Bode, W. et al., Inflammation, sepsis, and coagulation. Haematologica 1999, 84, 254-259.
50. Kolls, J. K., Oxidative stress in sepsis: a redox redux. J. Clin. Invest. 2006, 116, 860-863.
51. Victor, V. M., Rocha, M., De la Fuente, M., Immune cells: free radicals and antioxidants in sepsis. Int. Immunopharmacol. 2004, 4, 327-347.
52. Melo, E. S., Barbeiro, H. V., Ariga, S., Goloubkova, T. et al., Immune cells and oxidative stress in the endotoxin tolerance mouse model. Braz. J. Med. Biol. Res. 2010, 43, 57-67.
53. Siqueira-Batista, R., de Mendoca, E. G., Gomes, A. P., Vitorino, R. R. et al., Proteomic updates on sepsis. Rev. Assoc. Med. Bras. 2012, 58, 376-382.
54. Skibsted, S., Bhasin, M. K., Aird, W. C., Shapiro, N. I., Bench-to-bedside review: future novel diagnostics for sepsis-a systems biology approach. Crit. Care 2013, 17, doi:10.1186/cc12693.
55. Wong, H. R., Clinical review: sepsis and septic shock- the potential of gene arrays. Crit. Care 2012, 16, doi:10.1186/cc10537.
56. Wong, H. R., Cvijanovich, N., Allen, G. L., Lin, R. et al., Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum*. Crit. Care Med. 2009, 37, 1558-1566, 1510.1097/CCM.1550b1013e31819fcc31808.
57. Tang, B. M., Huang, S. J., McLean, A. S., Genome-wide transcription profiling of human sepsis: a systematic review. Crit. Care 2010, 14, doi:10.1186/cc9392.
58. Seymour, C., Yende, S., Scott, M., Pribis, J. et al., Metabolomics in pneumonia and sepsis: an analysis of the GenIMS cohort study. Intensive Care Med. 2013, 39, 1423-1434.
59. Stearns-Kurosawa, D. J., Osuchowski, M. F., Valentine, C., Kurosawa, S. et al., The pathogenesis of sepsis. Ann. Rev. Pathol. 2011, 6, 19-48.
60. Wright, P. C., Noirel, J., Ow, S. Y., Fazeli, A., A review of current proteomics technologies with a survey on their widespread use in reproductive biology investigations. Theriogenology 2012, 77, 738-765.e752.
61. Smith, J. C., Figeys, D., Proteomics technology in systems biology. Mol. BioSyst. 2006, 2, 364-370.
62. Cho, C.-K. J., Shan, S. J., Winsor, E. J., Diamandis, E. P., Proteomics analysis of human amniotic fluid. Mol. Cell. Proteomics 2007, 6, 1406-1415.
63. Yarmush, M. L., Jayaraman, A., Advances in proteomic technologies. Ann. Rev. Biomed. Eng. 2002, 4, 349-373.
64. Bantscheff, M., Lemeer, S., Savitski, M., Kuster, B., Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present. Anal. Bioanal. Chem. 2012, 404, 939-965.
65. Nguyen, A., Yaffe, M. B., Proteomics and systems biology approaches to signal transduction in sepsis. Crit. Care Med. 2003, 31, S1-S6.
66. Karvunidis, T., Mares, J., Thongboonkerd, V., Matejovic, M., Recent progress of proteomics in critical illness. Shock 2009, 31, 545-552.
67. Siqueira-Batista, R., Mendonça, E. G. d., Gomes, A. P., Vitorino, R. R. et al., Atualidades proteômicas na sepse. Rev. Assoc. Méd. Bras. 2012, 58, 376-382.
68. Dejager, L., Pinheiro, I., Dejonckheere, E., Libert, C., Cecal ligation and puncture: the gold standard model for polymicrobial sepsis? Trends Microbiol. 2011, 19, 198-208.
69. Anderson, N. L., Anderson, N. G., The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
70. Anderson, N. L., Polanski, M., Pieper, R., Gatlin, T. et al., The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol. Cell. Proteomics 2004, 3, 311-326.
71. Ray, S., Reddy, P. J., Jain, R., Gollapalli, K. et al., Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics 2011, 11, 2139-2161.
72. Fliser, D., Novak, J., Thongboonkerd, V., Argiles, A. et al., Advances in urinary proteome analysis and biomarker discovery. J. Am. Soc. Nephrol. 2007, 18, 1057-1071.
73. González-Buitrago, J. M., Ferreira, L., Lorenzo, I., Urinary proteomics. Clin. Chim. Acta 2007, 375, 49-56.
74. Halverson, S., Malani, P. N., Newton, D. W., Habicht, A. et al., Impact of hourly emergency department patient volume on blood culture contamination and diagnostic yield. J. Clin. Microbiol. 2013, 51, 1721-1726.
75. Goligorsky, M. S., Addabbo, F., O'Riordan, E., Diagnostic potential of urine proteome: a broken mirror of renal diseases. J. Am. Soc. Nephrol. 2007, 18, 2233-2239.
76. Tu, C., Rudnick, P. A., Martinez, M. Y., Cheek, K. L. et al., Depletion of abundant plasma proteins and limitations of plasma proteomics. J. Proteome Res. 2010, 9, 4982-4991.
77. Cao, Z., Yende, S., Kellum, J. A., Robinson, R. A. S., Additions to the human plasma proteome via a tandem MARS depletion iTRAQ-based workflow. Int. J. Proteomics 2013, 2013, 654356.
78. Shuford, C. M., Hawkridge, A. M., Burnett, J. C., Muddiman, D. C., Utilizing spectral counting to quantitatively characterize tandem removal of abundant proteins (TRAP) in human plasma. Anal. Chem. 2010, 82, 10179-10185.
79. Qian, W.-J., Kaleta, D. T., Petritis, B. O., Jiang, H. et al., Enhanced detection of low abundance human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy. Mol. Cell. Proteomics 2008, 7, 1963-1973.
80. Keidel, E.-M., Ribitsch, D., Lottspeich, F., Equalizer technology-equal rights for disparate beads. Proteomics 2010, 10, 2089-2098.
81. Bauer, M., Press, A. T., Trauner, M., The liver in sepsis: patterns of response and injury. Curr. Opin. Crit. Care 2013, 19, 123-127.
82. Hinkelbein, J., Kalenka, A., Schubert, C., Peterka, A. et al., Proteome and metabolome alterations in heart and liver indicate compromised energy production during sepsis. Protein Pept. Lett. 2010, 17, 18-31.
83. Wang, X., Zhao, H., Andersson, R., Proteomics and leukocytes: an approach to understanding potential molecular mechanisms of inflammatory responses. J. Proteome Res. 2004, 3, 921-929.
84. Weycker, D., Akhras, K. S., Edelsberg, J., Angus, D. C. et al., Long-term mortality and medical care charges in patients with severe sepsis. Crit. Care Med. 2003, 31, 2316-2323.
85. Arias, E., MacDorman, M. F., Strobino, D. M., Guyer, B., Annual summary of vital statistics-2002. Pediatrics 2003, 112, 1215-1230.
86. Johnson, C. E., Whitwell, J. K., Pethe, K., Saxena, K. et al., Term newborns who are at risk for sepsis: are lumbar punctures necessary? Pediatrics 1997, 99, e10.
87. Wynn, J. L., Scumpia, P. O., Delano, M. J., O'Malley, K. A. et al., Increased mortality and altered immunity in neonatal sepsis produced by generalized peritonitis. Shock 2007, 28, 675-683.
88. Martin, G. S., Mannino, D. M., Moss, M., The effect of age on the development and outcome of adult sepsis. Crit. Care Med. 2006, 34, 15-21.
89. Opal, S. M., Girard, T. D., Ely, E. W., The immunopathogenesis of sepsis in elderly patients. Clin. Infect. Dis. 2005, 41, S504-S512.
90. Sachse, C., Dressler, F., Henkel, E., Increased serum procalcitonin in newborn infants without infection. Clin. Chem. 1998, 44, 1343-1344.
91. Buhimschi, C. S., Bhandari, V., Han, Y. W., Dulay, A. T. et al., Using proteomics in perinatal and neonatal sepsis: hopes and challenges for the future. Curr. Opin. Infect. Dis. 2009, 22, 235-243.
92. Srinivasan, L., Harris, M. C., New technologies for the rapid diagnosis of neonatal sepsis. Curr. Opin. Pediatr. 2012, 24, 165-171.
93. Sampson, J. E., Theve, R. P., Blatman, R. N., Shipp, T. D. et al., Fetal origin of amniotic fluid polymorphonuclear leukocytes. Am. J. Obstet. Gynecol. 1997, 176, 77-81.
94. Buhimschi, I. A., Buhimschi, C. S., The role of proteomics in the diagnosis of chorioamnionitis and early-onset neonatal sepsis. Clin. Perinatol. 2010, 37, 355-374.
95. Buhimschi, I. A., Zhao, G., Rosenberg, V. A., Abdel-Razeq, S. et al., Multidimensional proteomics analysis of amniotic fluid to provide insight into the mechanisms of idiopathic preterm birth. PLoS ONE 2008, 3, e2049.
96. Buhimschi, C. S., Abdel-Razeq, S., Cackovic, M., Pettker, C. M. et al., Fetal heart rate monitoring patterns in women with amniotic fluid proteomic profiles indicative of inflammation. Am. J. Perinatol. 2008, 25, 359-372.
97. Buhimschi, C. S., Bhandari, V., Hamar, B. D., Bahtiyar, M.-O. et al., Proteomic profiling of the amniotic fluid to detect inflammation, infection, and neonatal Sepsis. PLoS Med. 2007, 4, e18.
98. Buhimschi, C. S., Buhimschi, I. A., Abdel-Razeq, S., Rosenberg, V. A. et al., Proteomic biomarkers of intra-amniotic inflammation: relationship with funisitis and early-onset sepsis in the premature neonate. Pediatr. Res. 2007, 61, 318-324.
99. Buhimschi, I. A., Christner, R., Buhimschi, C. S., Proteomic biomarker analysis of amniotic fluid for identification of intra-amniotic inflammation. BJOG 2005, 112, 173-181.
100. Buhimschi, C. S., Bhandari, V., Dulay, A. T., Nayeri, U. A. et al., Proteomics mapping of cord blood identifies haptoglobin "switch-on" pattern as biomarker of early-onset neonatal sepsis in preterm newborns. PLoS ONE 2011, 6, e26111.
101. Gravett, M. G., Novy, M. J., Rosenfeld, R. G., Reddy, A. P. et al., Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. JAMA 2004, 292, 462-469.
102. Rüetschi, U., Rosén, Å., Karlsson, G., Zetterberg, H. et al., Proteomic analysis using protein chips to detect biomarkers in cervical and amniotic fluid in women with intra-amniotic inflammation. J. Proteome Res. 2005, 4, 2236-2242.
103. González-López, A., Aguirre, A., López-Alonso, I., Amado, L. et al., MMP-8 deficiency increases TLR/RAGE ligands S100A8 and S100A9 and exacerbates lung inflammation during endotoxemia. PLoS ONE 2012, 7, e39940.
104. Ng, P. C., Ang, I. L., Chiu, R. W. K., Li, K. et al., Host-response biomarkers for diagnosis of late-onset septicemia and necrotizing enterocolitis in preterm infants. J. Clin. Invest. 2010, 120, 2989-3000.
105. Qian, W.-J., Jacobs, J. M., Camp, D. G., Monroe, M. E. et al., Comparative proteome analyses of human plasma following in vivo lipopolysaccharide administration using multidimensional separations coupled with tandem mass spectrometry. Proteomics 2005, 5, 572-584.
106. Gebhardt, C., Hirschberger, J., Rau, S., Arndt, G. et al., Use of C-reactive protein to predict outcome in dogs with systemic inflammatory response syndrome or sepsis. J. Vet. Emerg. Crit. Care 2009, 19, 450-458.
107. Cicarelli, D. D., Vieira, J. E., Benseñor, FE et al., Comparison of C-reactive protein and serum amyloid A protein in septic shock patients. Med. Inflamm. 2008, 2008, 631414.
108. Zweigner, J., Gramm, H.-J., Singer, O. C., Wegscheider, K. et al., High concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood 2001, 98, 3800-3808.
109. Rogers, C. L., Rozanski, E. A., von Willebrand factor antigen concentration in dogs with sepsis. J. Vet. Intern. Med. 2010, 24, 229-230.
110. 18O labeling and the accurate mass and time tag approach. Mol. Cell. Proteomics 2005, 4, 700-709.
111. Lee, R., Wang, D., Lin, N. T., Chen, H. I., Physiological and chemical indicators for early and late stages of sepsis in conscious rats. J. Biomed. Sci. 2002, 9, 613-621.
112. Shen, Z., Want, E. J., Chen, W., Keating, W. et al., Sepsis plasma protein profiling with immunodepletion, three-dimensional liquid chromatography tandem mass spectrometry, and spectrum counting. J. Proteome Res. 2006, 5, 3154-3160.
113. Kalenka, A., Feldmann, R. E., Otero, K., Maurer, M. H. et al., Changes in the serum proteome of patients with sepsis and septic shock. Anesth. Analg. 2006, 103, 1522-1526.
114. Paiva, R. A. d., David, C. M., Domont, G. B., Proteomics in sepsis: a pilot study. Rev. Bras. Ter. Intens. 2010, 22, 403-412.
115. Triantafilou, M., Mouratis, M.-A., Lepper, P. M., Haston, R. M. et al., Serum proteins modulate lipopolysaccharide and lipoteichoic acid-induced activation and contribute to the clinical outcome of sepsis. Virulence 2012, 3, 136-145.
116. Soares, A. J. C., Santos, M. F., Trugilho, M. R. O., Neves-Ferreira, A. G. C. et al., Differential proteomics of the plasma of individuals with sepsis caused by Acinetobacter baumannii. J. Proteomics 2009, 73, 267-278.
117. Cao, Z., Yende, S., Kellum, J. A., Angus, D. C. et al., Proteomics reveals age-related differences in the host immune response to sepsis. J. Proteome Res. 2013, doi:10.1021/pr400814s.
118. Markiewski, M. M., DeAngelis, R. A., Lambris, J. D., Complexity of complement activation in sepsis. J. Cell. Mol. Med. 2009, 12, 2245-2254.
119. Amaral, A., Opal, S., Vincent, J.-L., Coagulation in sepsis. Intensive Care Med. 2004, 30, 1032-1040.
120. Kale, S., Yende, S., Kong, L., Perkins, A. et al., The effects of age on inflammatory and coagulation-fibrinolysis response in patients hospitalized for pneumonia. PLoS ONE 2010, 5, e13852.
121. Su, L., Cao, L., Zhou, R., Jiang, Z. et al., Identification of novel biomarkers for sepsis prognosis via urinary proteomic analysis using iTRAQ labeling and 2D-LC-MS/MS. PLoS ONE 2013, 8, e54237.
122. Su, L., Zhou, R., Liu, C., Wen, B. et al., Urinary proteomics analysis for sepsis biomarkers with iTRAQ labeling and two-dimensional liquid chromatography-tandem mass spectrometry. J. Trauma Acute Care Surg. 2013, 74, 940-945.
123. Gadgil, H. S., Pabst, K. M., Giorgianni, F., Umstot, E. S. et al., Proteome of monocytes primed with lipopolysaccharide: analysis of the abundant proteins. Proteomics 2003, 3, 1767-1780.
124. Pabst, M. J., Pabst, K. M., Handsman, D. B., Beranova-Giorgianni, S. et al., Proteome of monocyte priming by lipopolysaccharide, including changes in interleukin-I beta and leukocyte elastase inhibitor. Proteome Sci. 2008, 6, doi:10.1186/1477-5956-6-13.
125. Zhang, H., Zhao, C., Li, X., Zhu, Y. et al., Study of monocyte membrane proteome perturbation during lipopolysaccharide-induced tolerance using iTRAQ-based quantitative proteomic approach. Proteomics 2010, 10, 2780-2789.
126. Fessler, M. B., Malcolm, K. C., Duncan, M. W., Worthen, G. S., A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase. J. Biol. Chem. 2002, 277, 31291-31302.
127. Karsan, A., Blonder, J., Law, J., Yaquian, E. et al., Proteomic analysis of lipid microdomains from lipopolysaccharide-activated human endothelial cells. J. Proteome Res. 2005, 4, 349-357.
128. Bowler, R. P., Reisdorph, N., Reisdorph, R., Abraham, E., Alterations in the human lung proteome with lipopolysaccharide. BMC Plum. Med. 2009, 9, doi:10.1186/1471-2466-9-20.
129. McDunn, J. E., Townsend, R. R., Cobb, J. P., The murine plasma protein response to polymicrobial intra-abdominal sepsis. Proteomics Clin. Appl. 2007, 1, 373-386.
130. Ren, Y., Wang, J., Xia, J., Jiang, C. et al., The alterations of mouse plasma proteins during septic development. J. Proteome Res. 2007, 6, 2812-2821.
131. Dear, J. W., Leelahavanichkul, A., Aponte, A., Hu, X. et al., Liver proteomics for therapeutic drug discovery: inhibition of the cyclophilin receptor CD147 attenuates sepsis-induced acute renal failure. Crit. Care Med. 2007, 35, 2319-2328.
132. Hinkelbein, J., Feldmann, R. E. J., Schubert, C., Peterka, A. et al., Alterations in rat serum proteome and metabolome as putative disease markers in sepsis. J. Trauma Acute Care Surg. 2009, 66, 1065-1075.
133. Hinkelbein, J., Feldmann, R. E. Jr, Peterka, A., Schubert, C. et al., Alterations in cerebral metabolomics and proteomic expression during sepsis. Curr. Neurovasc. Res. 2007, 4, 280-288.
134. Chen, H.-W., Kuo, H.-T., Hwang, L.-C., Kuo, M.-F. et al., Proteomic alteration of mitochondrial aldehyde dehydrogenase 2 in sepsis regulated by heat shock response. Shock 2007, 28, 710-716, 710.1097/shk.1090b1013e318050c318058c318052.
135. Hu, J.-y., Li, C.-L., Wang, Y.-W., Altered proteomic pattern in platelets of rats with sepsis. Blood Cells Mol. Dis. 2012, 48, 30-35.
136. Duan, X., Berthiaume, F., Yarmush, D., Yarmush, M. L., Proteomic analysis of altered protein expression in skeletal muscle of rats in a hypermetabolic state induced by burn sepsis. Biochem. J. 2006, 397, 149-158.
137. Holly, M. K., Dear, J. W., Hu, X., Schechter, A. N. et al., Biomarker and drug-target discovery using proteomics in a new rat model of sepsis-induced acute renal failure. Kidney Int. 2006, 70, 496-506.
138. Zhang, P.-h., Li, L.-l., Zeng, J.-z., Yang, L.-r. et al., Preliminary proteomic analysis of circulating polymorphonuclear neutrophils from rabbits experiencing scald injury and Staphylococcus aureus sepsis. Inflamm. Res. 2010, 59, 307-314.
139. Zhang, P.-h., Yang, L.-r., Li, L.-l., Zeng, J.-z. et al., Proteomic change of peripheral lymphocytes from scald injury and Pseudomonas aeruginosa sepsis in rabbits. Burns 2010, 36, 82-88.
140. Zhou, Z., Ren, J., Liu, H., Gu, G. et al., Serum proteomic analysis from bacteremic and leucopenic rabbits. J. Surg. Res. 2011, 171, 749-754.
141. Miller, S. I., Ernst, R. K., Bader, M. W., LPS, TLR4 and infectious disease diversity. Nat. Rev. Microbiol. 2005, 3, 36-46.
142. Deng, J. C., Cheng, G., Newstead, M. W., Zeng, X. et al., Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. J. Clin. Invest. 2006, 116, 2532-2542.
143. Du, R., Long, J., Yao, J., Dong, Y. et al., Subcellular quantitative proteomics reveals multiple pathway cross-talk that coordinates specific signaling and transcriptional regulation for the early host response to LPS. J. Proteome Res. 2010, 9, 1805-1821.
144. Chen, T., Lin, X., Xu, J., Tan, R. et al., Redox imbalance provokes deactivation of macrophages in sepsis. Proteomics Clin. Appl. 2009, 3, 1000-1009.
145. Lee, C. G., Da Silva, C. A., Dela Cruz, C. S., Ahangari, F. et al., Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Ann. Rev. Physiol. 2011, 73, 479-501.
146. Maddens, B., Ghesquière, B., Vanholder, R., Demon, D. et al., Chitinase-like proteins are candidate biomarkers for sepsis-induced acute kidney injury. Mol. Cell. Proteomics 2012, 11, doi:10.1074/mcp.M111.013094.
147. Tseng, H.-W., Juan, H.-F., Huang, H.-C., Lin, J. Y.-C. et al., Lipopolysaccharide-stimulated responses in rat aortic endothelial cells by a systems biology approach. Proteomics 2006, 6, 5915-5928.
148. Hack, C. E., Zeerleder, S., The endothelium in sepsis: source of and a target for inflammation. Crit. Care Med. 2001, 29, S21-S27.
149. Dauphinee, S. M., Karsan, A., Lipopolysaccharide signaling in endothelial cells. Lab Invest. 2005, 86, 9-22.
150. Tang, J., Chen, X., Tu, W., Guo, Y. et al., Propofol inhibits the activation of p38 through up-regulating the expression of Annexin A1 to exert its anti-inflammation effect. PLoS ONE 2011, 6, e27890.
151. Li, F. C. H., Chan, J. Y. H., Chan, S. H. H., Chang, A. Y. W., In the rostral ventrolateral edulla, the 70-kDa heat shock protein (HSP70), but not HSP90, confers neuroprotection against fatal endotoxemia via augmentation of nitric-oxide synthase I (NOS I)/protein kinase G signaling pathway and inhibition of NOS II/peroxynitrite cascade. Mol. Pharmacol. 2005, 68, 179-192.
152. Chang, A. Y. W., Chan, J. Y. H., Chou, J. L. J., Li, F. C. H. et al., Heat shock protein 60 in rostral ventrolateral medulla reduces cardiovascular fatality during endotoxaemia in the rat. J. Physiol. 2006, 574, 547-564.
153. Robichaud, S., Lalu, M., Udenberg, T., Schulz, R. et al., Proteomics analysis of changes in myocardial proteins during endotoxemia. J. Proteomics 2009, 72, 648-655.
154. Oveland, E., Karlsen, T. V., Haslene-Hox, H., Semaeva, E. et al., Proteomic evaluation of inflammatory proteins in rat spleen interstitial fluid and lymph during LPS-induced systemic inflammation reveals increased levels of ADAMST1. J. Proteome Res. 2012, 11, 5338-5349.
155. Shao, W., Yeretssian, G., Doiron, K., Hussain, S. N. et al., The caspase-1 digestome identifies the glycolysis pathway as a target during infection and septic shock. J. Biol. Chem. 2007, 282, 36321-36329.
156. Crouser, E., Julian, M., Huff, J., Mandich, D. et al., A proteomic analysis of liver mitochondria during acute endotoxemia. Intens. Care Med. 2006, 32, 1252-1262.
157. Struck, J., Ühlein, M., Morgenthaler, N. G., Fürst, W. et al., Release of the mitochondrial enzyme carbamoyl phosphate synthase under septic conditions. Shock 2005, 23, 533-538.
158. Thongboonkerd, V., Chiangjong, W., Mares, J., Moravec, J. et al., Altered plasma proteome during an early phase of peritonitis-induced sepsis. Clin. Sci. 2009, 116, 721-730.
159. Zhang, Z., Chan, D. W., The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol. Biomark. Prev. 2010, 19, 2995-2999.
160. Zhang, Z., Bast, R. C., Yu, Y., Li, J. et al., Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004, 64, 5882-5890.
161. Rai, A. J., Zhang, Z., Rosenzweig, J., Shih, I.-m. et al., Proteomic approaches to tumor marker discovery. Arch. Pathol. Lab. Med. 2002, 126, 1518-1526.
162. Pereira, S. R., Faça, V. M., Gomes, G. G., Chammas, R. et al., Changes in the proteomic profile during differentiation and maturation of human monocyte-derived dendritic cells stimulated with granulocyte macrophage colony stimulating factor/interleukin-4 and lipopolysaccharide. Proteomics 2005, 5, 1186-1198.
163. Wu, C. H. Y., Chan, J. Y. H., Chou, J. L.-J., Chan, S. H. H. et al., Engagement of ubiquitination and de-ubiquitination at rostral ventrolateral medulla in experimental brain death. J. Biomed. Sci. 2012, 19, doi:10.1186/1423-0127-19-48.